UK Column News - 2nd November 2022 - Huge money in jabs — even before people are born

- MHRA Board Meeting ticket booking time is here again
- Independent: Dozens of children vaccine-overdosed
- Health Service Journal (HSJ) Patient Safety Congress: £199 to hear the Patient Safety Commissioner, Dr Henrietta Hughes
- Citeline: the new name for Datamonitor pharmaceutical consultancy/intelligence
- Cambridge Cluster: more magic than medicine
- VacZine Analytics helps its clients predict the market for immune-based therapies
- Graphs show exponential growth of jab industry: trebled to £60 billion
- Cambridgeshire Live: Norovirus scare in Peterborough (see also Debi Evans' blog)
- Express: Young children flu season warning
- Forbes: First RSV vaccine on the horizon—Pfizer trial
- EndPoints News: Pfizer declares first-ever Phase III success for RSV vaccine in infants—immunity in utero
Appeal to viewers: Who is VacZine Analytics' John Savopoulos (pharmaceutical intelligence)? Is he related to the other Savopoulos noted at the company? What is his background?

Sources: https://www.ukcolumn.org/video/uk-column-news-2nd-november-2022
Archive on demand, UKC articles, latest discussions, community groups and more: https://community.ukcolumn.org/